Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting

Abstract Background Information is lacking from real‐life studies evaluating the efficacy of tildrakizumab in moderate‐to‐severe psoriasis. Materials and Methods We retrospectively analysed a database 30 patients with psoriasis (PsO) that were treated (100 mg, s.c.) followed for 36 weeks. Clinical (disease severity treatment response) was evaluated by Psoriasis Area Severity Index (PASI) at baseline after 4, 12, 24, The quality life (QoL) PsO measured using Dermatology Life Quality (DLQI). Results A PASI score <3 achieved weeks 86.7%, 100%, 100% patients, respectively (aged 46.3 ± 13.3 years) tildrakizumab. significantly decreased 17.6 4.7 to 1.1 3.9 4 12 remaining <1 up ( p < 0.001 vs. baseline), −75–90 −100 response 96.7%, 60% DLQI also (13.8 2.9) 3.6 1.6 weeks, 1.4 0.6 0 Week 24 baseline). Multivariate regression revealed effect on or independent predictor variables age, gender, BMI, disease duration, previous biologic, presence comorbidities. No adverse event reported during Conclusion This retrospective study shows real world‐setting effective safe